In June 2023, FDA issued the first draft guidance on clinical investigations involving psychedelics. The 11-page document offered pointers on everything from nonclinical research and chemistry, manufacturing, and controls through to clinical studies and abuse potential assessments. Since then, a round of stakeholder feedback had sat unaddressed for the better part of three years…
